ARDELYX, INC.

ARDX

ARDELYX, INC.

ARDX

Insider Sentiment (TTM):

Last Purchase:2026-02-20Last Sale:2026-06-18Shares Purchased (TTM):333,333Shares Sold (TTM):675,245

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:166,631,555Shares Outstanding:245,855,082Institutional Ownership Pct.:67.78%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	97	31	68	43	90	31	65	47	42	36	21	34
Available For Sale Securities Debt Securities Curr…	185	207	197	200	148	183	185	143	144	166	163	131
Accounts Receivable Net Current	100	83	72	77	63	46	58	53	37	28	22	43
Inventory Gross	26	23	18	25	22	24	21	11	14	10	12	9
Prepaid Expense And Other Assets Current	19	24	14	15	16	15	11	12	11	12	8	7
Assets Current	442	382	382	368	352	313	356	284	263	258	246	241
Property Plant And Equipment Net	2	2	2	2	2	2	1	1	1	1	1	1
Inventory Noncurrent	113	105	105	104	101	82	70	74	70	69	37	39
Operating Lease Right Of Use Asset	4	4	5	5	5	4	2	4	4	5	6	7
Other Assets Noncurrent	7	7	7	7	7	7	5	5	5	6	4	2
Assets	576	505	502	486	467	410	436	368	343	342	298	289
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	38	28	19	18	22	14	16	16	11	17	11	8
Employee Related Liabilities Current	15	9	19	15	12	7	15	12	10	7	13	8
Operating Lease Liability Current	2	2	1	1	1	1	2	3	4	4	4	4
Loans Payable Current	-	-	-	-	-	-	-	-	-	-	0	0
Contract With Customer Liability Current	7	3	1	7	6	11	11	7	11	7	7	4
Accrued Liabilities And Other Liabilities	71	67	48	42	41	43	35	33	27	22	15	19
Liabilities Current	132	110	89	83	82	76	78	70	62	57	50	44
Operating Lease Liability Noncurrent	3	3	4	4	4	3	1	1	1	1	2	3
Long Term Loans Payable	252	204	203	202	201	151	151	101	100	100	50	27
Contract With Customer Liability Noncurrent	14	14	14	14	12	8	7	13	10	12	9	10
Other Liabilities Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Liabilities	427	356	335	332	327	265	262	210	196	191	131	98
Stockholders Equity
Preferred Stock Value	-	-	-	-	-	-	-	-	-	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,150	1,133	1,114	1,101	1,085	1,072	1,059	1,048	1,036	1,024	1,013	1,009
Retained Earnings Accumulated Deficit	-1,001	-985	-947	-947	-946	-926	-885	-890	-889	-873	-846	-817
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	0	0	0	-0	-0	0	-0
Stockholders Equity	149	149	167	154	140	146	173	158	147	151	167	191
Liabilities And Stockholders Equity	576	505	502	486	467	410	436	368	343	342	298	289
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	0	0	0
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	-	-	5	5	5
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	0	0	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	249	247	244	243	241	239	238	237	235	234	232	232
Shares Outstanding	249	247	244	243	241	239	238	237	235	234	232	232

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.48%	-4.42%	-17.85%	-	-	-	-	-	-	-	-	-
2025	-27.42%	-34.92%	-19.38%	44.87%	26.20%	14.81%	8.18%	13.37%	34.73%	-14.24%	-8.31%	0.59%
2024	-0.59%	-9.28%	-18.85%	15.45%	11.45%	6.18%	-9.54%	-17.89%	-14.65%	-4.37%	-22.03%	-36.71%
2023	-	-	-	-	-	-	10.89%	60.76%	109.62%	-8.16%	-19.95%	-11.90%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.34	3.49	4.31	4.41	4.30	4.12	4.58	4.03	4.21	4.53	4.88	5.54
Quick Ratio	3.00	3.06	3.96	3.93	3.84	3.62	4.17	3.69	3.81	4.15	4.47	5.18
Working Capital	309.71M	272.30M	293.71M	284.60M	269.85M	236.85M	278.62M	213.60M	200.58M	201.04M	195.72M	197.69M
Leverage & Debt
Debt to Equity	2.86	2.39	2.00	2.15	2.35	1.82	1.51	1.32	1.34	1.27	0.78	0.51
Interest Coverage TTM	-1.60	-1.74	-2.04	-2.07	-2.54	-2.67	-2.15	-5.94	-6.91	-9.86	-12.78	-5.51
Debt Ratio	0.74	0.71	0.67	0.68	0.70	0.64	0.60	0.57	0.57	0.56	0.44	0.34
Efficiency & Turnover
Asset Turnover TTM	0.86	0.94	0.87	0.93	0.95	0.96	0.91	0.77	0.76	0.57	0.51	0.62
Days Sales Outstanding TTM	65.94	55.18	58.05	59.49	47.16	37.65	43.62	69.90	40.28	46.20	43.65	65.88
Receivables Turnover TTM	5.54	6.61	6.29	6.14	7.74	9.69	8.37	5.22	9.06	7.90	8.36	5.54
Per Share Metrics
Diluted EPS TTM	-0.22	-0.24	-0.26	-0.23	-0.24	-0.23	-0.17	-0.31	-0.28	-0.28	-0.30	-0.12
Free Cash Flow Per Share TTM	-0.07	-0.15	-0.18	-0.23	-0.23	-0.20	-0.19	-0.27	-0.37	-0.35	-0.41	-0.30
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	94.37%	92.51%	90.29%	88.21%	84.80%	84.59%	84.85%	85.16%	86.03%	85.30%	85.70%	88.17%
Operating Profit Margin TTM	-7.86%	-8.75%	-10.06%	-9.53%	-10.46%	-10.95%	-8.38%	-25.44%	-28.05%	-38.90%	-50.84%	-17.24%
Net Profit Margin TTM	-12.35%	-13.58%	-15.12%	-14.20%	-14.60%	-14.86%	-11.73%	-28.82%	-31.02%	-41.36%	-53.08%	-19.79%
Growth Metrics
Net Revenue Growth (1Y)	16.77%	18.24%	22.09%	58.12%	83.88%	127.33%	168.06%	87.57%	153.42%	152.32%	138.61%	1,390.41%
Net Income Growth (1Y)	-1.21%	7.99%	57.40%	-22.09%	-13.44%	-18.31%	-40.76%	173.18%	16.14%	-0.15%	-1.70%	-76.72%
EPS Growth (1Y)	-4.46%	4.82%	53.61%	-24.02%	-15.38%	-20.21%	-44.77%	157.97%	6.43%	-11.30%	-28.88%	-82.75%
Valuation Metrics
P/E TTM	-22.71	-25.36	-22.81	-23.57	-16.68	-21.79	-30.47	-22.39	-26.68	-25.85	-20.58	-34.21
P/B TTM	8.49	9.91	8.42	8.64	6.74	8.04	6.88	10.27	11.83	11.28	8.15	4.75
P/S TTM	2.81	3.44	3.45	3.35	2.44	3.24	3.57	6.45	8.28	10.69	10.93	6.77
Market Cap	1.27B	1.47B	1.41B	1.33B	940.52M	1.17B	1.19B	1.63B	1.74B	1.70B	1.36B	908.95M
Enterprise Value	1.17B	1.44B	1.34B	1.29B	850.48M	1.14B	1.13B	1.58B	1.70B	1.67B	1.34B	875.18M
Calculated Values
Free Cash Flow TTM	-17.92M	-37.50M	-43.98M	-55.35M	-55.19M	-48.73M	-45.82M	-63.80M	-85.82M	-81.12M	-90.06M	-67.07M
Net Debt	-97.19M	-31.21M	-68.00M	-42.72M	-90.05M	-30.81M	-64.93M	-47.43M	-41.89M	-36.15M	-21.47M	-33.77M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-18Sale

Owner: Williams, Laura A

Title: Chief Patient Officer

Shares: 81,898

Price/Share: $5.99

Value: $490,569.02

Shares Owned: 378,195

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Raab, Michael

Title: President & CEO

Shares: 41,666

Price/Share: $5.67

Value: $236,246.22

Shares Owned: 1,699,200

Relationship: Director,Officer

Ownership: Direct

2026-05-21Sale

Owner: Reilly, Joseph James

Title: See Remarks

Shares: 3,719

Price/Share: $6.27

Value: $23,318.13

Shares Owned: 149,107

Relationship: Officer

Ownership: Direct

2026-05-21Sale

Owner: Bishop, John E

Title: See Remarks

Shares: 2,306

Price/Share: $6.27

Value: $14,458.62

Shares Owned: 336,845

Relationship: Officer

Ownership: Direct

2026-05-21Sale

Owner: Foster, Eric Duane

Title: Chief Commercial Officer

Shares: 7,998

Price/Share: $6.27

Value: $50,147.46

Shares Owned: 417,972

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-18	Williams, Laura A	Officer	Chief Patient Officer	Direct	Sale	81,898	5.99	$490,569.02	378,195	4
2026-06-15	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	5.67	$236,246.22	1,699,200	4
2026-05-21	Reilly, Joseph James	Officer	See Remarks	Direct	Sale	3,719	6.27	$23,318.13	149,107	4
2026-05-21	Bishop, John E	Officer	See Remarks	Direct	Sale	2,306	6.27	$14,458.62	336,845	4
2026-05-21	Foster, Eric Duane	Officer	Chief Commercial Officer	Direct	Sale	7,998	6.27	$50,147.46	417,972	4
2026-05-21	Kelliher, Mike	Officer	Chief Business Officer	Direct	Sale	7,248	6.27	$45,444.96	357,418	4
2026-05-21	Brady, James Parker	Officer	Chief Human Resources Officer	Direct	Sale	1,846	6.27	$11,574.42	261,066	4
2026-05-21	Hohenleitner, Susan	Officer	Chief Financial Officer	Direct	Sale	1,455	6.27	$9,122.85	229,078	4
2026-05-21	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	54,748	6.27	$343,269.96	1,720,033	4
2026-05-21	Williams, Laura A	Officer	Chief Patient Officer	Direct	Sale	6,989	6.27	$43,821.03	429,093	4
2026-05-15	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	6.28	$261,662.48	1,774,781	4
2026-04-15	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,668	6.29	$262,091.72	1,795,614	4
2026-03-16	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	5.84	$243,329.44	1,816,448	4
2026-02-24	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	6.26	$260,829.16	1,836,153	4
2026-02-20	Mott, David M	Director	-	Direct	Purchase	333,333	5.84	$1,946,664.72	3,302,918	4
2026-02-20	Reilly, Joseph James	Officer	See Remarks	Direct	Sale	4,991	5.76	$28,748.16	151,790	4
2026-02-20	Foster, Eric Duane	Officer	Chief Commercial Officer	Direct	Sale	10,439	5.75	$60,024.25	425,970	4
2026-02-20	Hohenleitner, Susan	Officer	Chief Financial Officer	Direct	Sale	2,033	5.79	$11,771.07	230,533	4
2026-02-20	Bishop, John E	Officer	See Remarks	Direct	Sale	3,179	5.76	$18,311.04	339,151	4
2026-02-20	Brady, James Parker	Officer	Chief Human Resources Officer	Direct	Sale	2,543	5.79	$14,723.97	262,912	4
2026-02-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	45,982	5.74	$263,936.68	1,856,986	4
2026-02-20	Williams, Laura A	Officer	See Remarks	Direct	Sale	8,176	5.79	$47,339.04	436,082	4
2026-02-20	Kelliher, Mike	Officer	See Remarks	Direct	Sale	9,595	5.76	$55,267.20	364,666	4
2026-01-08	Williams, Laura A	Officer	Chief Patient Officer	Direct	Sale	50,000	6.98	$349,000.00	361,563	4
2025-11-21	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	5,995	5.54	$33,212.30	299,895	4
2025-11-21	Foster, Eric Duane	Officer	Chief Commercial Officer	Direct	Sale	5,814	5.54	$32,209.56	295,684	4
2025-11-21	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	46,887	5.54	$259,753.98	1,455,363	4
2025-11-21	Reilly, Joseph James	Officer	See Remarks	Direct	Sale	11,086	5.54	$61,416.44	108,914	4
2025-11-21	Williams, Laura A	Officer	Chief Patient Officer	Direct	Sale	6,426	5.54	$35,600.04	359,896	4
2025-11-21	Kelliher, Mike	Officer	See Remarks	Direct	Sale	5,560	5.54	$30,802.40	271,181	4
2025-08-26	Williams, Laura A	Officer	Chief Patient Officer	Direct	Sale	80,000	6.12	$489,600.00	366,322	4
2025-08-21	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	45,687	5.93	$270,923.91	1,502,250	4
2025-08-21	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	7,037	5.93	$41,729.41	409,052	4
2025-08-21	Foster, Eric Duane	Officer	Chief Commercial Officer	Direct	Sale	15,308	5.93	$90,776.44	301,498	4
2025-08-21	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	5,841	5.93	$34,637.13	305,890	4
2025-08-21	Kelliher, Mike	Officer	Chief Business Officer	Direct	Sale	5,417	5.93	$32,122.81	276,741	4
2025-08-21	Williams, Laura A	Officer	Chief Patient Officer	Direct	Sale	6,261	5.93	$37,127.73	396,322	4
2025-06-16	Mott, David M	Director	-	Direct	Purchase	200,000	3.63	$726,000.00	2,896,871	4
2025-06-09	Mott, David M	Director	-	Direct	Purchase	200,000	3.69	$738,000.00	2,696,871	4
2025-05-20	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	7,218	4.08	$29,449.44	416,089	4
2025-05-20	Kelliher, Mike	Officer	See Remarks	Direct	Sale	14,522	4.08	$59,249.76	282,158	4
2025-05-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	46,817	4.08	$191,013.36	1,547,937	4
2025-05-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	5,992	4.08	$24,447.36	311,731	4
2025-05-20	Foster, Eric Duane	Officer	Chief Commercial Officer	Direct	Sale	2,507	4.08	$10,228.56	316,806	4
2025-05-20	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	6,421	4.08	$26,197.68	402,583	4
2025-05-15	Mott, David M	Director	-	Direct	Purchase	100,000	3.29	$329,000.00	2,496,871	4
2025-05-02	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	4.25	$177,080.50	1,594,754	4
2025-05-02	Mott, David M	Director	-	Direct	Purchase	381,377	4.22	$1,609,410.94	2,396,871	4
2025-04-04	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	4.59	$191,246.94	1,615,587	4
2025-03-07	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,668	5.36	$223,340.48	1,635,138	4
2025-02-24	Mott, David M	Director	-	Direct	Purchase	77,729	5.00	$388,645.00	2,015,494	4
2025-02-20	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	4,941	5.62	$27,768.42	303,804	4
2025-02-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	22,964	5.62	$129,057.68	1,085,755	4
2025-02-20	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	5,171	5.62	$29,061.02	285,968	4
2025-02-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	4,291	5.62	$24,115.42	181,043	4
2025-01-31	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	5.36	$223,329.76	1,108,719	4
2025-01-21	Mott, David M	Director	-	Direct	Purchase	199,000	4.99	$993,010.00	1,937,765	4
2025-01-07	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	41,666	5.31	$221,246.46	1,129,552	4
2024-12-19	Mott, David M	Director	-	Direct	Purchase	213,300	4.67	$996,111.00	1,638,765	4
2024-12-10	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	25,000	5.26	$131,500.00	1,150,385	4
2024-11-25	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	25,000	5.38	$134,500.00	1,150,385	4
2024-11-20	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	7,366	4.79	$35,283.14	308,745	4
2024-11-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	31,980	4.79	$153,184.20	1,175,385	4
2024-11-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	7,046	4.79	$33,750.34	185,334	4
2024-11-20	Blanks, Robert	Officer	See Remarks	Direct	Sale	4,941	4.79	$23,667.39	314,421	4
2024-11-20	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	4,941	4.79	$23,667.39	297,005	4
2024-11-20	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	5,260	4.79	$25,195.40	291,139	4
2024-11-13	Mott, David M	Director	-	Direct	Purchase	215,868	4.62	$997,310.16	1,425,465	4
2024-11-11	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	2,743	4.90	$13,440.70	1,207,365	4
2024-11-06	Rosenbaum, David P.	Officer	Chief Development Officer	Indirect	Sale	27,171	6.10	$165,743.10	153,616	4
2024-11-04	Rosenbaum, David P.	Officer	Chief Development Officer	Indirect	Sale	27,172	5.95	$161,673.40	153,616	4
2024-10-28	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	25,000	5.91	$147,750.00	1,210,108	4
2024-10-11	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	7,500	6.01	$45,075.00	1,210,108	4
2024-09-27	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	49,564	6.92	$342,982.88	301,946	4
2024-09-26	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	3,000	6.07	$18,210.00	1,217,608	4
2024-09-13	Rosenbaum, David P.	Officer	Chief Development Officer	Indirect	Sale	5,312	6.26	$33,253.12	153,616	4
2024-09-11	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	35,000	5.61	$196,350.00	1,220,608	4
2024-08-27	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	7,500	6.22	$46,650.00	1,219,509	4
2024-08-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	7,089	5.86	$41,541.54	192,380	4
2024-08-20	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	7,412	5.86	$43,434.32	314,740	4
2024-08-20	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	4,969	5.86	$29,118.34	351,510	4
2024-08-20	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	5,289	5.86	$30,993.54	295,257	4
2024-08-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	32,225	5.86	$188,838.50	1,227,009	4
2024-08-20	Felsch, Robert Ora	Officer	See Remarks	Direct	Sale	3,567	5.86	$20,902.62	91,560	4
2024-08-20	Blanks, Robert	Officer	See Remarks	Direct	Sale	4,969	5.86	$29,118.34	319,362	4
2024-08-16	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	20,000	5.94	$118,800.00	356,479	4
2024-08-12	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	1,229	5.71	$7,017.59	1,259,234	4
2024-07-29	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	30,000	5.64	$169,200.00	1,260,463	4
2024-07-15	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	7,500	5.97	$44,775.00	1,260,463	4
2024-06-28	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	2,310	6.59	$15,222.90	1,267,963	4
2024-06-21	Blanks, Robert	Officer	See Remarks	Direct	Sale	38,000	5.96	$226,480.00	324,331	4
2024-06-13	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	35,000	6.65	$232,750.00	1,270,273	4
2024-06-05	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	145,000	7.12	$1,032,400.00	322,152	4
2024-06-03	Rosenbaum, David P.	Officer	Chief Development Officer	Indirect	Sale	17,872	7.00	$125,104.00	158,502	4
2024-05-29	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	7,500	6.72	$50,400.00	1,270,273	4
2024-05-21	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	31,484	7.81	$245,890.04	1,277,773	4
2024-05-21	Rodriguez, Susan	Officer	Chief Commercial Officer	Direct	Sale	6,703	7.81	$52,350.43	449,092	4
2024-05-21	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	4,855	7.81	$37,917.55	376,479	4
2024-05-21	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	5,167	7.81	$40,354.27	300,546	4
2024-05-21	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	6,927	7.81	$54,099.87	199,469	4
2024-05-21	Blanks, Robert	Officer	See Remarks	Direct	Sale	4,855	7.81	$37,917.55	362,331	4
2024-05-21	Felsch, Robert Ora	Officer	See Remarks	Direct	Sale	3,485	7.81	$27,217.85	95,127	4
2024-05-21	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	4,794	7.81	$37,441.14	367,152	4
2024-05-14	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	3,000	7.99	$23,970.00	1,307,933	4
2024-05-06	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	284,170	8.88	$2,523,429.60	203,760	4
2024-05-06	Felsch, Robert Ora	Officer	See Remarks	Direct	Sale	207,988	8.80	$1,830,294.40	95,947	4
2024-05-03	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	39,949	8.35	$333,574.15	370,189	4
2024-05-03	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	45,000	9.00	$405,000.00	267,993	4
2024-04-29	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	30,000	6.40	$192,000.00	1,310,933	4
2024-04-15	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	7,500	7.06	$52,950.00	1,310,933	4
2024-04-01	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	1,518	7.31	$11,096.58	1,318,433	4
2024-03-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	86,000	7.73	$664,780.00	312,993	4
2024-02-26	Rosenbaum, David P.	Officer	Chief Development Officer	Indirect	Sale	5,183	9.20	$47,683.60	175,936	4
2024-02-20	Felsch, Robert Ora	Officer	See Remarks	Direct	Sale	2,352	8.75	$20,580.00	184,834	4
2024-02-20	Rodriguez, Susan	Officer	Chief Commercial Officer	Direct	Sale	6,928	8.75	$60,620.00	452,795	4
2024-02-20	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	5,341	8.75	$46,733.75	304,835	4
2024-02-20	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	4,803	8.75	$42,026.25	380,138	4
2024-02-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	22,917	8.75	$200,523.75	1,319,951	4
2024-02-20	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	5,017	8.75	$43,898.75	378,985	4
2024-02-20	Blanks, Robert	Officer	See Remarks	Direct	Sale	5,017	8.75	$43,898.75	368,186	4
2024-02-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	4,432	8.75	$38,780.00	398,993	4
2024-02-08	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	15,344	9.18	$140,857.92	384,002	4
2024-01-08	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	30,000	6.64	$199,200.00	286,596	4
2023-12-26	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	225,000	6.36	$1,431,000.00	182,426	4
2023-12-18	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	5,675	6.07	$34,447.25	316,596	4
2023-12-14	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	7,000	5.55	$38,850.00	322,271	4
2023-12-11	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	50,000	5.08	$254,000.00	275,675	4
2023-12-08	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	20,000	5.27	$105,400.00	329,271	4
2023-12-05	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	10,272	5.00	$51,360.00	349,271	4
2023-11-30	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	3,000	4.50	$13,500.00	359,543	4
2023-11-20	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	11,368	4.36	$49,564.48	867,868	4
2023-11-20	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	2,384	4.36	$10,394.24	325,675	4
2023-11-20	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	2,835	4.36	$12,360.60	362,543	4
2023-11-20	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	2,873	4.36	$12,526.28	332,426	4
2023-11-20	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	2,581	4.36	$11,253.16	266,191	4
2023-11-20	Blanks, Robert	Officer	See Remarks	Direct	Sale	2,835	4.36	$12,360.60	260,453	4
2023-11-20	Felsch, Robert Ora	Officer	See Remarks	Direct	Sale	1,044	4.36	$4,551.84	117,066	4
2023-11-20	Rodriguez, Susan	Officer	Chief Commercial Officer	Direct	Sale	4,714	4.36	$20,553.04	346,973	4
2023-11-15	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	25,000	4.00	$100,000.00	266,839	4
2023-10-10	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	1,644	4.00	$6,576.00	365,378	4
2023-09-08	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	2,897	4.55	$13,181.35	367,022	4
2023-08-21	Rosenbaum, David P.	Officer	Chief Development Officer	Direct	Sale	2,846	3.55	$10,103.30	369,919	4
2023-08-21	Rodriguez, Susan	Officer	Chief Commercial Officer	Direct	Sale	4,733	3.55	$16,802.15	348,687	4
2023-08-21	Felsch, Robert Ora	Officer	See Remarks	Direct	Sale	1,048	3.55	$3,720.40	115,110	4
2023-08-21	Grammer, Elizabeth A	Officer	See Remarks	Direct	Sale	2,392	3.55	$8,491.60	328,059	4
2023-08-21	Blanks, Robert	Officer	See Remarks	Direct	Sale	2,846	3.55	$10,103.30	263,288	4
2023-08-21	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	2,591	3.55	$9,198.05	291,839	4
2023-08-21	Raab, Michael	Director,Officer	President & CEO	Direct	Sale	11,419	3.55	$40,537.45	876,236	4
2023-08-21	Renz, Justin A	Officer	Chief Financial Officer	Direct	Sale	2,884	3.55	$10,238.20	333,849	4
2023-06-27	Williams, Laura A	Officer	Chief Medical Officer	Direct	Sale	25,000	3.35	$83,750.00	294,430	4
2023-06-23	Blanks, Robert	Officer	See Remarks	Direct	Sale	33,333	3.63	$120,998.79	266,134	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

67.78%

Inst. Shares: 166,631,555

Shares Outstanding: 245,855,082

2025-12-31

68.55%

Inst. Shares: 165,222,180

Shares Outstanding: 241,033,750

2025-09-30

66.06%

Inst. Shares: 159,814,431

Shares Outstanding: 241,908,407

2025-06-30

68.23%

Inst. Shares: 163,707,206

Shares Outstanding: 239,928,570

2025-03-31

66.55%

Inst. Shares: 158,792,540

Shares Outstanding: 238,624,145

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	166,631,555	245,855,082	67.78%
2025-12-31	165,222,180	241,033,750	68.55%
2025-09-30	159,814,431	241,908,407	66.06%
2025-06-30	163,707,206	239,928,570	68.23%
2025-03-31	158,792,540	238,624,145	66.55%
2024-12-31	148,268,780	235,232,927	63.03%
2024-09-30	136,840,596	235,911,399	58.01%
2024-06-30	139,511,722	234,571,192	59.48%
2024-03-31	134,826,832	233,065,960	57.85%
2023-12-31	129,961,699	219,331,253	59.25%
2023-09-30	117,525,567	222,782,229	52.75%
2023-06-30	119,512,106	214,951,127	55.60%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ARDELYX, INC. (ARDX) — SEC Financial Statements & Analysis

ARDELYX, INC. (ARDX) is a pharmaceutical preparations company, incorporated in DE. ARDELYX, INC. trades on Nasdaq as: ARDX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ARDELYX, INC. reported a 16.77% year-over-year revenue growth, a Gross Profit Margin of 94.37% (TTM), a Debt-to-Equity ratio of 2.86x, a Price-to-Sales (P/S) ratio of 2.81x (TTM), a Price-to-Book (P/B) ratio of 8.49x (TTM), at a market cap of $1.27B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 16.77%
Gross Profit Margin TTM: 94.37%
Debt To Equity: 2.86x
P/S TTM: 2.81x
P/B TTM: 8.49x
Market Cap: $1.27B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ARDELYX, INC. in?

ARDELYX, INC. (ARDX) operates in the Pharmaceutical Preparations industry.

What is ARDX's market cap?

ARDELYX, INC. (ARDX) has a market capitalization of $1.27B as of 2026-06-30.

What exchange does ARDX trade on?

ARDELYX, INC. (ARDX) trades on the Nasdaq.

Where is ARDELYX, INC. incorporated?

ARDELYX, INC. is incorporated in DE.

ARDELYX, INC.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

ARDELYX, INC. (ARDX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

ARDELYX, INC. (ARDX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.